Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03154190
Other study ID # VAR0134
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 8, 2017
Est. completion date August 30, 2022

Study information

Verified date January 2022
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.


Description:

PRIMARY OBJECTIVES: I. To reduce acute care utilization by 2-5% for advanced cancer patients by training and deploying health care coaches who help patients and families discuss care goals, virtual modalities, engage in shared-decision-making, and participate in educational activities. SECONDARY OBJECTIVES: I. To improve patients' experience of their care. II. Improve patient understanding of advanced care planning. III. To improve the receipt of goal concordant care. IV. To reduce total healthcare costs. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive usual care. ARM B: Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms. After completion of study, patients are followed up for 6 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 128
Est. completion date August 30, 2022
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Newly diagnosed patients for the following conditions - Colon cancer stage III and IV - Rectal cancer stage II, III, IV - Glioblastoma multiforme (brain) -- no stage - Non-small cell lung cancer stage IIIA, IIIB, IV - Small cell lung cancer, limited stage and extensive stage - Castration-resistant prostate cancer - Head and neck cancer stage III and IV - Gastric cancer stage III and IV - Esophageal cancer stage III and IV - Pancreatic cancer stage II, III, IV - Renal cell carcinoma, stage IV - Breast cancer, stage IV, if triple negative ER/PR/H2N negative or on systemic chemotherapy - Sarcoma, stage IV - Bladder carcinoma, stage IV - Acute myeloid leukemia - Melanoma, stage III and IV - Ovarian cancer, stage III and IV - High grade myelodysplastic syndrome (MDS) - Any patient with recurrent or progressive cancer - Patients must have the ability to understand and willingness to sign a written informed consent document - Patient must have ongoing oncologic needs and plan to receive all care at the study institution and not already be in hospice or home-care Exclusion Criteria: - Patients must have capacity to consent - Pregnant patients are excluded

Study Design


Related Conditions & MeSH terms

  • Acute Myeloid Leukemia
  • Brain Glioblastoma
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Ovarian Epithelial
  • Carcinoma, Renal Cell
  • Colonic Neoplasms
  • Disease Progression
  • Esophageal Neoplasms
  • Estrogen Receptor Negative
  • Extensive Stage Small Cell Lung Carcinoma
  • Glioblastoma
  • Head and Neck Carcinoma
  • HER2/Neu Negative
  • Hormone-Resistant Prostate Cancer
  • Limited Stage Small Cell Lung Carcinoma
  • Lung Neoplasms
  • Melanoma
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndromes
  • Osteosarcoma
  • Ovarian Neoplasms
  • Pancreatic Neoplasms
  • Progesterone Receptor Negative
  • Progressive Disease
  • Rectal Neoplasms
  • Recurrent Carcinoma
  • Sarcoma
  • Skin Neoplasms
  • Small Cell Lung Carcinoma
  • Stage II Pancreatic Cancer
  • Stage II Rectal Cancer
  • Stage IIA Pancreatic Cancer
  • Stage IIA Rectal Cancer
  • Stage IIB Pancreatic Cancer
  • Stage IIB Rectal Cancer
  • Stage IIC Rectal Cancer
  • Stage III Colon Cancer
  • Stage III Esophageal Cancer
  • Stage III Gastric Cancer
  • Stage III Non-Small Cell Lung Cancer
  • Stage III Ovarian Cancer
  • Stage III Pancreatic Cancer
  • Stage III Rectal Cancer
  • Stage III Skin Melanoma
  • Stage IIIA Colon Cancer
  • Stage IIIA Esophageal Cancer
  • Stage IIIA Gastric Cancer
  • Stage IIIA Non-Small Cell Lung Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IIIA Rectal Cancer
  • Stage IIIA Skin Melanoma
  • Stage IIIB Colon Cancer
  • Stage IIIB Esophageal Cancer
  • Stage IIIB Gastric Cancer
  • Stage IIIB Non-Small Cell Lung Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIB Rectal Cancer
  • Stage IIIB Skin Melanoma
  • Stage IIIC Colon Cancer
  • Stage IIIC Esophageal Cancer
  • Stage IIIC Gastric Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IIIC Rectal Cancer
  • Stage IIIC Skin Melanoma
  • Stage IV Bladder Cancer
  • Stage IV Bone Sarcoma
  • Stage IV Breast Cancer
  • Stage IV Colon Cancer
  • Stage IV Esophageal Cancer
  • Stage IV Gastric Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Stage IV Ovarian Cancer
  • Stage IV Pancreatic Cancer
  • Stage IV Rectal Cancer
  • Stage IV Renal Cell Cancer
  • Stage IV Skin Melanoma
  • Stage IV Soft Tissue Sarcoma
  • Stage IVA Bone Sarcoma
  • Stage IVA Colon Cancer
  • Stage IVA Rectal Cancer
  • Stage IVB Bone Sarcoma
  • Stage IVB Colon Cancer
  • Stage IVB Rectal Cancer
  • Stomach Neoplasms
  • Triple-Negative Breast Carcinoma

Intervention

Other:
Best Practice
Receive usual care
Laboratory Biomarker Analysis
Correlative studies
Procedure:
Supportive Care
Undergo health care coach support
Other:
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Virginia K Crosson Cancer Center Fullerton California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Emergency Department Visit (Chart Review) Emergency Department use for each patient will be abstracted by electronic medical record chart review for each patient at 6 months after enrollment. We will evaluate comparisons of emergency department visits between study arms. 6 months after patient enrollment
Primary Hospitalization Visits (Chart Review) Hospitalization use for each patient will be abstracted by electronic medical record chart review for each patient at 6 months after enrollment. We will evaluate comparisons of hospitalizations between the two study arms. 6 months after patient enrollment
Secondary Change in patient satisfaction with care and decision making among patients undergoing health care coach support as assessed by Consumer Assessment of Healthcare Providers and Systems-G and Patient Satisfaction with Decision Scale Each patient will receive a satisfaction with decision-making survey (The Satisfaction with Decision Survey) at 3 months, 6 months, 9 months, and 12 months. Change in patient satisfaction with care and decision making from 3 months to 6, 9, and 12 months
Secondary Change in patient satisfaction with care among patients undergoing health care coach support as assessed by Consumer Assessment of Healthcare Providers and Systems-G. Each patient will receive a satisfaction with care survey (The Consumer Assessment of Healthcare Providers and Systems-G) at 3 months, 6 months, 9 months, and 12 months. Change in patient satisfaction with care from 3 months to 6, 9, and 12 months
Secondary Emergency Department Visit (Chart Review) Emergency Department use for each patient will be abstracted by electronic medical record chart review for each patient at 12 months after enrollment. We will evaluate comparisons of emergency department visits between study arms. 12 months after patient enrollment
Secondary Emergency Department Visit (Chart Review) Emergency Department use for each patient will be abstracted by electronic medical record chart review for each patient who has died. We will evaluate comparisons of emergency department visits between study arms. 30 days prior to death
Secondary Hospitalization Visits (Chart Review) Hospital use for each patient will be abstracted by electronic medical record chart review for each patient at 12 months after enrollment. We will evaluate comparisons of hospitalization use between study arms. 12 months after patient enrollment
Secondary Hospitalization Visits (Chart Review) Hospital use for each patient will be abstracted by electronic medical record chart review for each patient who has died. We will evaluate comparisons of hospitalization use between study arms. 30 days prior to death
Secondary Hospice Consult (Chart Review) Hospice use for each patient will be abstracted by electronic medical record chart review for each patient at 12 months after enrollment. We will evaluate comparisons of hospice use between study arms. 6 months after patient enrollment
Secondary Hospice Consult (Chart Review) Hospice use for each patient will be abstracted by electronic medical record chart review for each patient at 12 months after enrollment. We will evaluate comparisons of hospice use between study arms. 12 months after patient enrollment
Secondary Hospice Consult (Chart Review) Hospice use for each patient will be abstracted by electronic medical record chart review for each patient who has died. We will evaluate comparisons of hospice use between study arms. 30 days prior to death
Secondary Palliative Care Consult (Chart Review) Palliative Care consult for each patient will be abstracted by electronic medical record chart review for each patient at 12 months after enrollment. We will evaluate comparisons of palliative care use between study arms. 6 months after patient enrollment
Secondary Palliative Care Consult (Chart Review) Palliative Care consult for each patient will be abstracted by electronic medical record chart review for each patient at 12 months after enrollment. We will evaluate comparisons of palliative care use between study arms. 12 months after patient enrollment
Secondary Palliative Care Consult (Chart Review) Palliative Care consult for each patient will be abstracted by electronic medical record chart review for each patient who has died. We will evaluate comparisons of palliative care use between study arms. 30 days prior to death
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2